U-Chart Analysis:Eisai Co.,Ltd.:4523

※The values of financial statements might be different from the actual ones. Please confirm the original. [instructions]

Main FunctionHelp Company NameHelp CodeHelp Types of IndustryHelp Market Name Fiscal Year End Year of Listing
Browse U-Chart Add to 'Companies Comparison' list Compare Lustrum Ullet index Eisai Co.,Ltd. Go to web site 4523 Medicals 東証プライム March 1, 2000 1961.
Analysis u.gifU-Chart AnalysisHelp hikaku.gifAdd to 'Companies Comparison' listHelp u2.gifCompare LustrumHelp mark.gifUllet indexHelp
Accounts Information Balance Sheet Profit and Loss Account Cash Flow Statement
Display

Eisai Co.,Ltd. Balance Sheet(B/S)

[Show - Hide] U-Chart:Balance Sheet (B/S)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Eisai Co.,Ltd. Balance Sheet 2024年3月期 Eisai Co.,Ltd. Balance Sheet 2023年3月期 Eisai Co.,Ltd. Balance Sheet 2022年3月期 Eisai Co.,Ltd. Balance Sheet 2021年3月期 Eisai Co.,Ltd. Balance Sheet 2020年3月期

[Show - Hide] Balance Sheet (B/S)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Cash and Cash Equivalents 277,477 267,350 309,633 248,740 254,244
Other Current AssetsHelp 445,506 354,852 330,973 269,604 267,161
Tangible Fixed AssetsHelp 164,894 166,633 169,926 160,933 144,638
Intangible Fixed AssetHelp 85,493 89,230 95,451 106,419 106,094
Investments and OthersHelp 184,063 176,468 141,574 130,948 121,321
Total AssetsHelp 1,393,799 1,263,350 1,239,315 1,088,427 1,062,140
Total Current LiabilitiesHelp 383,412 378,487 395,600 336,918 329,068
Total Long-term LiabilitiesHelp 134,773 84,904 94,893 49,908 54,945
Shareholder's EquityHelp 875,614 799,959 748,822 701,601 678,127
Total LiabilitiesHelp 1,393,799 1,263,350 1,239,315 1,088,427 1,062,140

Eisai Co.,Ltd. Profit and Loss Account(P/L)

[表示非表示] U-Chart:Profit and Loss Account (P/L)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Eisai Co.,Ltd. Profit and Loss Account 2024年3月期 Eisai Co.,Ltd. Profit and Loss Account 2023年3月期 Eisai Co.,Ltd. Profit and Loss Account 2022年3月期 Eisai Co.,Ltd. Profit and Loss Account 2021年3月期 Eisai Co.,Ltd. Profit and Loss Account 2020年3月期

[Show - Hide] Profit and Loss Account (P/L)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Amount of Sales 741,751 744,402 756,226 645,942 695,621
Total Sales 741,751 744,402 756,226 645,942 695,621
Cost of SalesHelp 155,333 177,776 165,603 161,257 167,548
Other Costs and RevenueHelp 544,012 511,194 542,669 442,743 406,306
Total CostsHelp 699,345 688,970 708,272 604,000 573,854
Net RevenueHelp 586,418 566,626 590,623 484,685 528,073
Earnings Before TaxHelp 61,823 45,012 54,458 52,296 128,063
Net IncomeHelp 42,406 55,432 47,954 41,942 121,767
Net Income 42,406 55,432 47,954 41,942 121,767

Eisai Co.,Ltd. Cash Flow Statement(C/F)

[表示非表示] U-Chart:Cash Flow Statement (C/F)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Eisai Co.,Ltd. Cash Flow Statement 2024年3月期 Eisai Co.,Ltd. Cash Flow Statement 2023年3月期 Eisai Co.,Ltd. Cash Flow Statement 2022年3月期 Eisai Co.,Ltd. Cash Flow Statement 2021年3月期 Eisai Co.,Ltd. Cash Flow Statement 2020年3月期

[Show - Hide] Cash Flow Statement (C/F)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Operating Cash Flow(OFC)Help 55,994 -1,772 117,589 73,067 102,782
Investing Cash Flow(ICF)Help -25,321 -22,723 -28,848 -36,086 -27,625
Financing Cash FlowHelp -22,720 -24,522 -48,967 -55,908 -103,528
Exchange Difference of Cash and Cash EquivalentsHelp 29,375 6,735 21,118 13,424 -9,309
Net Increase and Decrease in Cash and Cash Equivalentsn 37,328 -42,282 60,892 -5,503 -37,680

他社比較Help

Companies in 'Companies Comparison' list

Browsing historyHelp

Your reecently viewed companies

Eisai Co.,Ltd.

Company where related level is highHelp

Oncolys BioPharma Inc.
PeptiDream Inc.
Otsuka Holdings Co.,Ltd.
RIBOMIC Inc.
SanBio Company Limited
Delta-Fly Pharma,Inc.
Cyfuse Biomedical K.K.
Mitsubishi Tanabe Pharma Corporation
HEALIOS K.K.
KYORIN Pharmaceutical Co., Ltd.